The leading physicians from Accentia Biopharmaceuticals, Inc. and Johns Hopkins University have presented plans for a randomized clinical trial to study Cyrevia (formerly Revimmune) in multiple sclerosis (MS) to a number of key opinion leaders in the field and potential site investigators. Johns Hopkins University will serve as the lead trial site for the study.
Physicians also co-hosted a meeting with prospective clinical trial investigators at the recent American Academy of Neurology (AAN) Annual Meeting in New Orleans.
A group of invited key opinion leaders and neurologists from leading Multiple Sclerosis Centres of Excellence attended the Cyrevia investigators meeting, hearing presentations from two Johns Hopkins physicians: Douglas E Gladstone, MD, associate professor of Oncology, clinical director in-patient/out-patient programme (IPOP), Sidney Kimmel Comprehensive Cancer Centre; and Daniel M Harrison, MD, assistant professor of Neurology. Drs Gladstone and Harrison reviewed multiple open-label phase II Cyrevia studies conducted at Johns Hopkins, demonstrating significant benefit for Cyrevia versus historical outcomes in the treatment of a range of autoimmune diseases, and jointly proposed a controlled, randomized, multi-centre phase III MS study.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/2018